Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
about
Hypometabolism as a therapeutic target in Alzheimer's diseaseThe apolipoprotein E gene, attention, and brain functionRegulation of the high-affinity choline transporter activity and trafficking by its association with cholesterol-rich lipid raftsCombining heterogenous data for prediction of disease related and pharmacogenesCannabis and Cannabis ExtractsAcetylcholine receptor and behavioral deficits in mice lacking apolipoprotein ELong-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice.Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease.Apolipoprotein E: a major piece in the Alzheimer's disease puzzle.Biological changes associated with healthy versus pathological aging: a symposium review.The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.Clinical rationale of genetic testing in dementiaEffects of insulin and octreotide on memory and growth hormone in Alzheimer's diseaseDonepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.Science, medicine, and the future: Postgenomic technologies: hunting the genes for common disordersThe potential applications of Apolipoprotein E in personalized medicinePharmacogenomics: the genomics of drug response.The use of single-nucleotide polymorphism maps in pharmacogenomics.Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife.Advances in pharmacogenetics and pharmacogenomics.Alzheimer's disease: current knowledge, management and researchCauses of Alzheimer's diseaseRole of vascular risk factors and vascular dysfunction in Alzheimer's disease.Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?Single nucleotide polymorphisms and the future of genetic epidemiology.Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses.Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues.The status of ongoing trials for mild cognitive impairment.Applied neurogenomics.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Gene identification in Alzheimer's disease.Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy.Candidate gene case-control association studies: advantages and potential pitfalls.Candidate gene approach for pharmacogenetic studies.Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers.Proteomic identification of biomarkers of vascular injury.Ethical perspectives on pharmacogenomic profiling in the drug development process.Pharmacogenomics: the future of drug therapy.
P2860
Q21262020-0C1881E9-2211-4BE0-B03A-8AB5D82650ACQ24539024-88632F1D-EDB9-4AA0-9AFD-79239D26D4DFQ28576772-AE25EB9B-E149-425F-BDA2-F33FC915137CQ28659646-7E21CD0D-F82C-4C3D-B422-C50CA6FD746BQ30040327-4E6ECC69-F5EE-41A8-8F89-9DC61476E909Q30471824-D27CC27D-E7E3-495D-B0F1-95083C13E70EQ30473882-73073099-26D5-46E2-966C-FDDCDBA7B594Q32091544-5EA35F6C-EE3E-485C-A89A-34EFBC6BA92FQ33337322-0334FFD9-B70A-4142-8802-27B113E7ACAFQ33416543-00D2910F-4F5C-4D42-A487-1B7AC1B08FCFQ33624389-02459DE6-4DEE-449C-8DE9-6F3CF88CBA99Q33637687-35DE8F39-27B8-43B3-B415-B65C550ACA7EQ33694502-A555A389-7427-4D9D-AF2A-C86F7089D5C0Q33714955-9B3CFC07-012E-40E6-AE59-C1B9051962F4Q33742199-CC0A4E61-3541-4621-85B9-C93086674164Q33791482-EDF15E2B-CAC1-40F0-81BA-46EF4F026838Q33805200-E2A1A69D-0018-474C-B172-682310C00AF4Q33858831-E0ECEBF4-EDB4-4884-8186-A0E5D109FDB5Q33910630-6E16C8A2-407E-4919-87C8-F67AAFA14EB7Q33913441-33A808FC-0A54-4B08-A1CC-3ABC21B52121Q33931093-EF370625-7E14-4912-A29D-94A06C367F80Q34024117-5037A2BD-B3E8-40A5-9EEA-11A95CECA716Q34025936-27EAE050-360A-41FB-99A5-78A15ABBF3DFQ34037204-E68109FD-7A6F-4973-A9B5-2E48BBC69AECQ34055011-0C181499-079C-432E-93AE-6950D4253E45Q34058281-5DD76A0B-186A-48BD-A374-04ADF5B364D1Q34081504-5209969A-39D8-4339-87B0-66BEE2487DB9Q34093070-791098B1-7581-46CE-9C0C-CB96BE6C8210Q34145767-37CBFF9C-B590-4CFD-A5C7-B38EECE4FCCDQ34204390-1244FC8A-18B5-41D2-AB4A-60A31D571665Q34258228-952D4024-03D8-4225-B9A6-103C932C785BQ34327769-B839A523-B801-4429-831C-4DA96BAB8D3FQ34355252-88104356-DDEB-4605-AD5A-BBB0D84F2C8BQ34368342-EC04A7BE-E83D-4D5F-A121-0985117ECEEAQ34459045-95436D09-DDF8-4BA0-A49F-277B45D33AEEQ34609133-0D066EEF-548E-452D-B254-A0BA215F5888Q34660846-2BC7E9C0-D177-4B14-AFA4-4CD29335EB07Q34667425-35C70BB7-9485-44C3-93FF-92031108A90EQ34743306-A2A5A2E6-88ED-4925-85EF-0C67FE20585EQ34952587-98312109-C0DD-489B-B833-447D01EFC554
P2860
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@ast
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@en
type
label
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@ast
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@en
prefLabel
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@ast
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@en
P2093
P2860
P356
P1476
Apolipoprotein E4 allele as a ...... outcome in Alzheimer disease.
@en
P2093
Bertrand P
Delisle MC
Gauthier S
Nalbantoglu J
P2860
P304
12260-12264
P356
10.1073/PNAS.92.26.12260
P407
P577
1995-12-01T00:00:00Z